CA3025665A1 - Compounds for delivering glutathione to a target and methods of making and using the same - Google Patents

Compounds for delivering glutathione to a target and methods of making and using the same Download PDF

Info

Publication number
CA3025665A1
CA3025665A1 CA3025665A CA3025665A CA3025665A1 CA 3025665 A1 CA3025665 A1 CA 3025665A1 CA 3025665 A CA3025665 A CA 3025665A CA 3025665 A CA3025665 A CA 3025665A CA 3025665 A1 CA3025665 A1 CA 3025665A1
Authority
CA
Canada
Prior art keywords
aryl
compound
heteroaryl
aliphatic
heteroaliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025665A
Other languages
English (en)
French (fr)
Inventor
Joseph S. Beckman
Tory M. Hagen
Pamela R. Beilby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
Original Assignee
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University filed Critical Oregon State University
Publication of CA3025665A1 publication Critical patent/CA3025665A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3025665A 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same Pending CA3025665A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348030P 2016-06-09 2016-06-09
US62/348,030 2016-06-09
PCT/US2017/036393 WO2017214297A1 (en) 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3025665A1 true CA3025665A1 (en) 2017-12-14

Family

ID=60578926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025665A Pending CA3025665A1 (en) 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same

Country Status (7)

Country Link
US (2) US20190106456A1 (OSRAM)
EP (1) EP3468563B1 (OSRAM)
JP (3) JP7482495B2 (OSRAM)
AU (1) AU2017277532B2 (OSRAM)
CA (1) CA3025665A1 (OSRAM)
IL (1) IL263469B (OSRAM)
WO (1) WO2017214297A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456825B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向的谷胱甘肽衍生物纳米制剂及应用
CN113480595B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向谷胱甘肽衍生物、制备方法及应用
WO2024172390A1 (ko) * 2023-02-13 2024-08-22 가톨릭대학교 산학협력단 신규한 미토콘드리아 표적화 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6747009B2 (en) * 2002-09-19 2004-06-08 Universiteit Leiden Peptidomimetic glutathione analogs
AU2004293477A1 (en) * 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
WO2013177293A1 (en) 2012-05-22 2013-11-28 Biogen Idec Ma Inc. Trapping reagents for reactive metabolites screening
US20160129070A1 (en) 2014-11-10 2016-05-12 South Dakota Board Of Regents Glutathione Disulfide Compositions and Related Methods for the Treatment of Cancer

Also Published As

Publication number Publication date
EP3468563B1 (en) 2023-09-13
AU2017277532A1 (en) 2018-12-20
EP3468563A1 (en) 2019-04-17
IL263469A (en) 2019-01-31
JP2019518029A (ja) 2019-06-27
WO2017214297A1 (en) 2017-12-14
JP2022137094A (ja) 2022-09-21
US20250282817A1 (en) 2025-09-11
JP7482495B2 (ja) 2024-05-14
AU2017277532B2 (en) 2022-09-15
IL263469B (en) 2022-08-01
EP3468563A4 (en) 2020-07-29
JP2024150504A (ja) 2024-10-23
US20190106456A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
US20250282817A1 (en) Compounds for delivering glutathione to a target and methods of making and using the same
EP0717736B1 (en) Phosphorus derivatives to treat aids
CA2903103A1 (en) Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CN105764909B (zh) 用于治疗泛酸激酶相关神经变性(pkan)的稳定泛酰巯基乙胺衍生物及用于合成这样的化合物的方法
JP2017510570A (ja) 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
JP2024001064A (ja) 治療用金属錯体およびリガンドならびにその作成および使用の方法
US6677376B1 (en) Non-peptidic cyclophilin binding compounds and their use
KR102678696B1 (ko) 크레아틴 전구약물, 조성물과 이의 사용 방법
CN111187202B (zh) Nmda拮抗剂前药
ES2992410T3 (es) Inhibidores cetónicos de la lisina gingipaína
US9133141B2 (en) Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
US20040208822A1 (en) New quaternary ammonium compounds
ES2911284T3 (es) Derivados de indolizina, composición y métodos de uso
US9821008B2 (en) Inhibitors of ERCC1-XPF and methods of using the same
US12162856B2 (en) β-catenin and B-cell lymphoma 9 (BCL9) inhibitors
US20070185072A1 (en) Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
Alnabari et al. New quinone-amino acid conjugates linked via a vinylic spacer
US20240254098A1 (en) Thioester prodrugs for the treatment of renal anomalies
CN114127078B (zh) 杂化合物及其使用方法
Albanyan Synthesis and evaluation of l-cystine crystallization inhibitors and prodrugs for cystinuria
CN120435486A (zh) 用于肾脏疾病靶向治疗的肽-药物偶联物
WO2020118179A1 (en) Peptidomimetic inhibitors of β-catenin/tcf protein–protein interaction
BR112019004864B1 (pt) Inibidores cetona de lisina gingipain, composição farmacêutica e uso

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220405

EEER Examination request

Effective date: 20220405

EEER Examination request

Effective date: 20220405

EEER Examination request

Effective date: 20220405

EEER Examination request

Effective date: 20220405

EEER Examination request

Effective date: 20220405